文献速递脊柱关节炎

合并症数量对强直性脊柱炎患者结局指标及首个抗肿瘤坏死因子药物保留率的影响:REGISPONSER-AS 注册研究两年随访

Impact of the number of comorbidities on the outcome measures and on the retention rate of the first anti-TNF in patients with Ankylosing Spondylitis. Two-year follow-up in REGISPONSER-AS.
PubMed 文献 · Semin Arthritis Rheum · 2021-12-31

本研究为 REGISPONSER-AS 注册研究中的观察性前瞻性研究,随访 2 年,按基线合并症数量将强直性脊柱炎患者分为 0、1、≥2 三组。结果显示合并症≥2 组的整体 VAS、BASDAI、ASDAS、BASFI 及 SF12 躯体成分评分在基线和随访期间均更差,首个抗肿瘤坏死因子药物停用概率更高但差异未达统计学显著(log-rank 检验 P=0.180)。

要点

  • 合并症≥2 的强直性脊柱炎患者在基线和 2 年随访时整体 VAS、BASDAI、ASDAS、BASFI 评分更高,SF12 躯体成分评分更差。
  • 首个抗肿瘤坏死因子药物停用率在合并症≥2 组为 38.2%,0 组合并症组为 26.6%,1 组合并症组为 25.4%,组间差异未达统计学显著(log-rank 检验 P=0.180)。
  • 合并症≥2 与 2 年随访时结局指标评分更差相关,并呈现首个抗肿瘤坏死因子药物停用倾向更高。

核心结论

  • 在强直性脊柱炎患者中,存在 2 个或以上合并症与 2 年随访时结局指标评分更差相关,并呈现首个抗肿瘤坏死因子药物停用倾向更高。

研究设计与样本

  • 本研究为 REGISPONSER-AS 注册研究中进行的观察性前瞻性研究,随访 2 年。
  • 患者根据基线合并症数量分为 0、1 或≥2 三组。
  • 采用校正病程、年龄、性别和吸烟的线性回归模型评估合并症数量与患者报告结局评分的关联,采用校正病程、年龄、性别和吸烟的重复测量混合模型评估 2 年随访期间合并症数量对患者报告结局的影响,采用 log-rank 检验评估三组间首个抗肿瘤坏死因子抗体保留率。

主要发现

  • 合并症≥2 的患者在基线和 2 年随访期间整体 VAS、BASDAI、ASDAS 和 BASFI 评分更高,SF12 躯体成分评分更差。
  • 首个抗肿瘤坏死因子药物停用概率在合并症≥2 组为 38.2%,合并症 0 组为 26.6%,合并症 1 组为 25.4%,组间差异未达统计学显著(log-rank 检验 P=0.180)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the impact of the number of comorbidities on the outcome measures after two years of follow-up in patients with Ankylosing Spondylitis (AS) and to determine whether the number of comorbidities influences the retention rate of the first anti-TNF. METHODS: This was an observational and prospective study conducted during 2 years of follow-up in the REGISPONSER-AS registry. The patients were divided into three groups according to the number of comorbidities at baseline (0, 1 or ≥2). Linear regression models adjusted for disease duration, age, sex and smoking were constructed to evaluate the association between the number of comorbidities and the Patient Reported Outcomes (PRO) scores. The impact of the number of comorbidities on PROs over two years of follow-up was evaluated using mixed models for repeated measures adjusted for disease duration, age, sex and smoking. Finally, the retention rate of the first anti-TNF antibody across the three groups was evaluated using a log-rank test. RESULTS: Patients with two or more comorbidities showed higher scores at baseline and during the two years of follow-up for the Global VAS, BASDAI, ASDAS, and BASFI and worse scores for the physical component of the SF12. A higher probability of discontinuation of the first anti-TNF was found in patients with 2 or more comorbidities compared with the patients in the other groups (38.2% vs. 26.6% vs. 25.4% for ≥2 comorbidities, 0 and 1 comorbidity, respectively), although these differences were not significant (log-rank test: p-value = 0.180). CONCLUSION: In patients with AS, the presence of 2 or more comorbidities was associated with worse scores on the outcome measures test after two years of follow-up and a greater tendency of discontinuation for the first anti-TNF.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Puche-Larrubia MÁ, Ladehesa-Pineda L, Gómez-García I, et al. Impact of the number of comorbidities on the outcome measures and on the retention rate of the first anti-TNF in patients with Ankylosing Spondylitis. Two-year follow-up in REGISPONSER-AS. Semin Arthritis Rheum. 2021. PMID: 35027249. doi:10.1016/j.semarthrit.2021.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。